

# Lenny Dang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3388489/publications.pdf>

Version: 2024-02-01

7  
papers

911  
citations

1306789  
7  
h-index

1719596  
7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

1491  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. <i>Blood Cells, Molecules, and Diseases</i> , 2022, 95, 102660.	0.6	9
2	A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. <i>Blood</i> , 2022, 140, 2053-2062.	0.6	34
3	The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a $\beta^2$ -thalassemia mouse model. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	39
4	Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 101-107.	1.3	99
5	Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 300-305.	1.3	292
6	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 478-493.	7.7	350
7	AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. <i>Blood</i> , 2017, 130, 1347-1356.	0.6	88